Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221

Trial Profile

An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Expanded access
  • Acronyms DCVax-L EAP
  • Sponsors Northwest Biotherapeutics
  • Most Recent Events

    • 04 Jun 2019 Follow-up survival data, presented in a Northwest Biotherapeutics media release.
    • 27 Mar 2015 Survival data in 51 patients published in Northwest Biotherapeutics media release.
    • 27 Mar 2015 Survival data in 51 patients presented at 2nd Immunotherapy of Cancer (ITOC) Conference in Germany, according to a Northwest Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top